Henlius NDA for 120 mg denosumab biosimilar accepted by NMPA
Shanghai Henlius Biotech says China’s NMPA accepted its NDA for HLX14, a 120 mg denosumab biosimilar.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.